Release no 22/2010

Copenhagen and Oslo, 30th June, 2010

Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today
Wednesday, 30th June 2010 at 11:00 a.m. held an extraordinary general meeting at
Næsseslottet, Dronninggårds Allé 136, DK-2840 Holte.

The following decisions were made:

The board of directors' motion to change the company's currently effective
general guidelines for incentive payment for the Board of Directors and
executive management of Affitech A/S was adopted.

The board of directors' motion to authorise the board of directors to increase
the share capital was adopted.

The board of directors' motion to authorise the board of directors to issue
warrants was adopted.

The board of directors' motion to amend a number of provisions in the company's
articles of association, also as a result of the new Danish Companies Act was
adopted.

The board of directors' motion to include an article regarding the language at
general meeting etc. was adopted.

The chairman of the meeting was authorised to file any resolutions required to
be registered with the Commerce and Companies agency.

--------------------------------------------------------------------------------
| For more information please contact Affitech A/S: |
--------------------------------------------------------------------------------
| Martin Welschof, Managing Director | Randi Krogsgaard, Corporate |
| | Communications |
| Tel # +47 95 12 81 37 | Tel # +45 2320 1001 |
--------------------------------------------------------------------------------

About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company headquartered in Copenhagen, Denmark with R&D facilities in
Oslo, Norway. The company utilizes a range of proprietary antibody technologies
for the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS? (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to cell
surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS?. Further information is available at
www.affitech.com.
Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein.